Viatris Inc (VTRS): Capital Expenditures
$378.80M
Year ended 2025-12-31
$376.00M
Trailing 12 months to 2026-06-30
-2.3%
3-year compound annual growth
+9.3%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $378.80M | +16.2% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $326.00M | -13.5% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $377.00M | -7.1% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $406.00M | -11.2% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $457.20M | +88.1% | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | $243.00M | +14.0% | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | $213.20M | -15.4% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $252.10M | n/a | 2021-03-01, From 2018-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Viatris Inc (VTRS) | 2025-12-31 | $378.80M | +16.2% |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $898.40M | +18.9% |
| Vertex Pharmaceuticals Inc (VRTX) | 2025-12-31 | $437.60M | +47.0% |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $501.00M | +0.6% |
| Bausch Health Companies Inc. (BHC) | 2025-12-31 | $397.00M | +17.8% |
| Zoetis Inc. (ZTS) | 2025-12-31 | $621.00M | -5.2% |
| Organon & Co. (OGN) | 2025-12-31 | $162.00M | -7.4% |
| BeOne Medicines Ltd. (ONC) | 2025-12-31 | $185.84M | -62.3% |
| Elanco Animal Health Inc (ELAN) | 2025-12-31 | $276.00M | +87.8% |
Compare VTRS, REGN, VRTX, TEVA side by side · Screen every company in Pharmaceutical Preparations ↗